How These Biotech's Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma

Jun 23, 2016, 07:30 ET from Chelmsford Park SA

NEW YORK, June 23, 2016 /PRNewswire/ --

The Biotechnology industry might still be in rough waters, but it continues to present great opportunities to investors. assesses the recent performances of our featured companies for today: Intrexon Corp. (NYSE: XON), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Learn more about these stocks and receive your complimentary trade alerts at:  

To access full PDF Research Packages for free, please visit the links below.



(You may have to copy and paste the links into your browser)

XON Research Package:

VRTX Research Package:

ARNA Research Package:

REGN Research Package:


Germantown, Maryland-based Intrexon Corp.'s stock finished Wednesday's session 0.52% lower at $24.65 with a total volume of 1.29 million shares traded. Shares of the Company, which operates in the synthetic biology field in the U.S., are trading below their 50-day moving average by 13.19%. The stock has a Relative Strength Index (RSI) of 38.94.

On Wednesday, shares in Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc. ended the session at $85.22, slightly down 0.07%. The stock recorded a trading volume of 1.92 million shares. The Company's shares have gained 0.95% in the last one month and 6.33% in the previous three months. The stock is trading 1.98% below its 50-day moving average. Moreover, shares of Vertex Pharmaceuticals, which engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases, have an RSI of 39.15.

San Diego, California-based  biopharmaceutical Company, Arena Pharmaceuticals Inc.'s stock ended yesterday's session 1.07% lower at $1.85 and with a total volume of 1.14 million shares traded. The Company's shares have advanced 14.20% in the past month and 3.35% over the previous three months. The stock is trading 4.72% above its 50-day moving average. Additionally, shares of Arena Pharmaceuticals, which discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the U.S. and South Korea, have an RSI of 49.46.

At the close on Wednesday, shares in Tarrytown, New York headquartered biopharmaceutical Company, Regeneron Pharmaceuticals Inc., recorded a trading volume of 1.80 million shares, which was above their three months average volume of 924,230 shares. The stock finished 1.96% higher at $351.92. The Company's shares are trading below their 50-day moving average by 9.16%. Furthermore, shares of Regeneron Pharmaceuticals, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions globally, have an RSI of 32.50.


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA